RxDoctor Payments Data

Nahel Al Bouz, MD

Internal Medicine · Upland, CANPI 1326235136

Payments from drug & device makers

$1,145in general payments, 2019–2025

Across 57 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$230
  • Pfizer$189
  • Lilly USA, LLC$107
  • Novartis$107
  • Novo Nordisk$81
  • Johnson & Johnson$71
  • plus $360 from 12 others

What the payments were for

  • Food & beverage$1,10096%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,145 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$68,483
Medicare patients
121
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$114,942
JardianceEmpagliflozin107$114,286
OzempicSemaglutide56$79,650
Teriparatide22$78,681
TrulicityDulaglutide68$78,460
TradjentaLinagliptin73$67,277
ProliaDenosumab37$62,613
XareltoRivaroxaban47$49,592
JanuviaSitagliptin Phosphate44$46,160
XifaxanRifaximin11$41,689
MounjaroTirzepatide36$41,285
Repatha SyringeEvolocumab27$29,932
FarxigaDapagliflozin Propanediol29$28,988
JanumetSitagliptin Phos/Metformin Hcl29$21,578
Praluent PenAlirocumab21$13,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$55$192,931193 claims
Lilly USA, LLCTrulicity, Mounjaro$107$119,745104 claims
PfizerEliquis, Paxlovid$189$116,293106 claims
Novo NordiskOzempic$81$79,65056 claims
Alvogen IncTeriparatide$52$78,68122 claims
AmgenProlia$230$62,61337 claims
Johnson & JohnsonXarelto$71$49,59247 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$41,68911 claims
AstraZenecaFarxiga$17$28,98829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →